logo
NasdaqGS:SCPH logo

scPharmaceuticals Community

NasdaqGS:SCPH Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

SCPH logo
scPharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts

FDA Approval And Medicare Redesign Will Transform CKD Treatment Access

Key Takeaways FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities. Medicare redesign is set to increase patient demand, improve prescription fill rates, and positively impact profit margins.
View narrative
US$15.17
FV
81.0% undervalued intrinsic discount
76.63%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
2 days ago author updated this narrative